课题基金 / 基金详情

CCTN - FEMALE SITES - EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES

CCTN - FEMALE SITES - EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES
CCTN - 女性网站 - 长效可逆避孕药的评估
批准号:
9923500
负责人:
KATHARINE WHITE
金额:
$34.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-25 至 2022-09-27

项目摘要

项目成果

KATHARINE WHITE的其他基金

相似基金

相关文献

中文摘要
翻译
评价长效可逆避孕药(LARC)在育龄妇女中的避孕效果、插入疼痛、出血模式、相关痉挛、脱落率以及其他安全性和副作用。 Eunice Kennedy Shriver国家儿童健康和人类发展研究所(NICHD)的避孕药具发现和开发分支(CDDB)致力于开发长效可逆避孕药的新方法,为可能存在某些避孕产品风险因素的妇女提供安全有效的避孕措施,并降低静脉血栓栓塞症(VTE)的风险。 铜宫内节育器(IUD)是宫内系统的一个例子,它提供了长效避孕的好处,没有外源性激素或中断正常的月经周期。
英文摘要
To evaluate contraceptive efficacy, pain of insertion, bleeding patterns, associate cramping, expulsion rates as well as other safety and side effects of the long acting reversible contraceptive (LARCs) in women of reproductive age. The Contraceptive Discovery and Development Branch (CDDB) under the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is committed to develop new methods that are long acting reversible contraceptives that can provide safe and effective contraception for women who may have risk factors against some contraceptive products as well as reduce the risk of venous thromboembolism (VTE). The copper intrauterine devices (IUDs) are example of intrauterine systems that provide long acting contraceptive benefits without exogenous hormones or disruption of the regular menstrual cycle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM – NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK, FEMAILE SITES-CORE FUNCTION ACTIVITIES
  • 批准号:
    10897677
  • 项目类别:
  • 资助金额:
    $0.18万
  • 财政年份:
    2020
  • 负责人:
    KATHARINE WHITE
  • 依托单位:
CCTN - FEMALE SITES - EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES
  • 批准号:
    9152426
  • 项目类别:
  • 资助金额:
    $33.78万
  • 财政年份:
    2015
  • 负责人:
    KATHARINE WHITE
  • 依托单位:
海外基金